GLP-1 Resource Center

Why am I losing muscle on GLP-1 medications, and how to stop it

Muscle loss during GLP-1 treatment is not a side effect in the traditional sense. It is a predictable consequence of significant caloric restriction that is not commonly disclosed to patients before they start treatment.

The evidence

Multiple clinical studies have demonstrated that up to 40% of total weight lost on GLP-1 medications is lean muscle mass rather than fat. Research published in Obesity Reviews in 2026 highlighted this as one of the most underappreciated consequences of GLP-1 treatment.

Why it happens

When the body is in a significant caloric deficit, it does not burn fat exclusively. It draws on all available energy sources, including lean muscle tissue. Without adequate protein intake and creatine supplementation, the body will continue to break down muscle alongside fat throughout treatment.

The consequences extend beyond aesthetics. Muscle loss reduces resting metabolic rate, making it harder to continue losing weight over time. It contributes to the fatigue and weakness many GLP-1 patients experience. And it is one of the primary drivers of weight regain after stopping medication, because a lower muscle mass means a lower baseline calorie burn.

What the evidence supports

Protein intake. Most guidelines suggest 1.2 to 1.6g of protein per kilogram of body weight during active weight loss. On a suppressed appetite, hitting this target through food alone is difficult for most GLP-1 patients. See how to get enough protein on Ozempic for practical strategies.

Creatine monohydrate. 5,000mg daily is one of the most extensively studied supplements for lean mass preservation. It protects existing muscle from being used as fuel during caloric restriction. See the research behind TAKE Build for the specific studies supporting this dose.

Resistance exercise. Exercise during GLP-1 treatment, particularly resistance training two to three times per week, significantly reduces the proportion of weight lost from lean mass. This is the most important non-supplemental intervention available.

The connection to body composition outcomes

Patients who protect lean mass during GLP-1 treatment emerge with better body composition, higher resting metabolic rate, better skin appearance (lean mass supports skin structure as fat is lost), and lower risk of weight regain. Protecting lean mass is not just about aesthetics. It determines the long-term success of GLP-1 treatment.

The TAKE approach

TAKE Build delivers 5,000mg of creatine monohydrate with a full electrolyte complex. TAKE Nourish provides 20g of complete plant protein per serving. Both form The Strength System.

These statements have not been evaluated by the Food and Drug Administration. TAKE products are not intended to diagnose, treat, cure, or prevent any disease. Always consult your healthcare provider before starting any new supplement.